Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial.

@article{Ganser1988RecombinantHG,
  title={Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial.},
  author={Antonia Ganser and Bernd V{\"o}lkers and J. Greher and Oliver Gerhard Ottmann and Fabienne Walther and Regine Becher and Lothar Bergmann and Gregor Schulz and Dieter F Hoelzer},
  journal={Blood},
  year={1988},
  volume={73 1},
  pages={
          31-7
        }
}
In a phase I/II study, 11 patients with myelodysplastic syndromes (MDS) and severe transfusion-dependent cytopenia were treated with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) to investigate the effects of rhGM-CSF on normal hematopoiesis and leukemic cells. The treatment schedule included dose escalation from 15 micrograms/m2 to 150 micrograms/m2 administered by continuous intravenous (IV) infusion for seven to 14 days and was repeated after a two-week… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

Myelodysplastic syndromes in the elderly.

  • Cancer control : journal of the Moffitt Cancer Center
  • 2001

Similar Papers

Loading similar papers…